New chemo regimen shows promise for childhood leukemia
NCT ID NCT03165851
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looked back at 320 children with acute myeloid leukemia (AML) who received one of two chemotherapy regimens between 2005 and 2015. The newer approach used a risk-based strategy and more intensive chemotherapy. Researchers compared survival, relapse, and remission rates to see if the newer plan worked better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy (dose-dense intensive chemotherapy with high-dose cytarabine)
What this could lead to
If the newer regimen proves better, it could become a standard treatment for childhood AML, improving survival and remission rates.
What could go wrong
This is a retrospective comparison, not a randomized trial, so results may be less reliable. Chemotherapy has significant side effects, and the study does not test a new drug or cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, PEDIATRIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
InstituteHBDH
Tianjin, Tianjin Municipality, 300020, China